PDCD1 and non-small cell lung carcinoma: Additionally, previous studies have shown that in stage IV or recurring non-small-cell lung cancer (NSCLC), patients with high TMB have longer periods of PD-1 blockade when receiving first-line nivolumab compared with platinum-based chemotherapy.